Literature DB >> 27659504

Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis?

Vasiliki-Kalliopi Bournia1, George Kitas1, Athanasios D Protogerou1, Petros P Sfikakis1.   

Abstract

Although large-scale population studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of myocardial infarction, this is not confirmed in patients with rheumatoid arthritis (RA). Herein, we review the litterature on the differential effects of NSAIDs on cardiovascular risk in osteoarthritis (OA) versus RA and discuss possible explanations for this discrepancy. To assess a potential additive effect of age in non-RA populations, we compared weighted mean age between RA patients and unselected NSAID users included in cohort and case-control studies that estimate the cardiovascular risk of NSAIDs, assuming that the main indication for NSAID usage in elderly populations is OA. Our hypothesis that advanced age in osteoarthtitis compared to RA patients confounds the effect of NSAIDs on cardiovasular risk was not confirmed. Several other hypotheses that can be proposed to explain this counterintuitive effect of NSAIDs on the cardiovascular risk of RA patients are discussed. We conclude that patients with RA have a lower cardiovascular disease risk associated with the use of NSAIDs, probably due to the nature of their disease per se, until further research indicates differently.

Entities:  

Keywords:  Cardiovascular disease risk; Non-steroidal anti-inflammatory drugs; Osteoarthritis; Rheumatoid arthritis

Mesh:

Substances:

Year:  2016        PMID: 27659504     DOI: 10.1080/14397595.2016.1232332

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  4 in total

1.  Vascular Age, Metabolic Panel, Cardiovascular Risk and Inflammaging in Patients With Rheumatoid Arthritis Compared With Patients With Osteoarthritis.

Authors:  Gabriel-Santiago Rodríguez-Vargas; Pedro Santos-Moreno; Jaime-Andrés Rubio-Rubio; Paula-Katherine Bautista-Niño; Darío Echeverri; Luz-Dary Gutiérrez-Castañeda; Fabio Sierra-Matamoros; Stephania Navarrete; Anggie Aparicio; Luis Saenz; Adriana Rojas-Villarraga
Journal:  Front Cardiovasc Med       Date:  2022-07-05

Review 2.  Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases.

Authors:  Aikaterini Arida; Athanasios D Protogerou; George D Kitas; Petros P Sfikakis
Journal:  Int J Mol Sci       Date:  2018-06-27       Impact factor: 5.923

3.  Limonin Inhibits IL-1β-Induced Inflammation and Catabolism in Chondrocytes and Ameliorates Osteoarthritis by Activating Nrf2.

Authors:  Jie Jin; Xinhuang Lv; Ben Wang; Chenghao Ren; Jingtao Jiang; Hongyu Chen; Ximiao Chen; Mingbao Gu; Zongyou Pan; Naifeng Tian; Aimin Wu; Liaojun Sun; Weiyang Gao; Xiangyang Wang; Xiaolei Zhang; Yaosen Wu; Yifei Zhou
Journal:  Oxid Med Cell Longev       Date:  2021-11-09       Impact factor: 6.543

4.  Controlled release of optimized electroporation enhances the transdermal efficiency of sinomenine hydrochloride for treating arthritis in vitro and in clinic.

Authors:  Shun Feng; Lijun Zhu; Zhisheng Huang; Haojia Wang; Hong Li; Hua Zhou; Linlin Lu; Ying Wang; Zhongqiu Liu; Liang Liu
Journal:  Drug Des Devel Ther       Date:  2017-06-15       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.